-

SHAREHOLDER ALERT: Robbins LLP Announces That 360 DigiTech, Inc. (QFIN) Is Being Sued for Misleading Shareholders

SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of 360 DigiTech, Inc. (NASDAQ: QFIN) between April 30, 2020 and July 7, 2021, for violations of the Securities Exchange Act of 1934. 360 DigiTech, through its subsidiaries, operates a digital consumer finance platform, providing online consumer products to the borrowers funded by institutional funding partners.

If you suffered a loss due to 360 DigiTech Inc.'s misconduct, click here.

360 DigiTech, Inc. (QFIN) Made False and Misleading Statements Regarding its Business, Operations, and Prospects

According to the complaint, during the relevant period, defendants touted the Company's dedication to privacy protections and data security of its borrowers' information. The truth, however, was that the Company had been collecting personal information in violation of relevant Chinese laws and regulations and therefore, was exposed to an increased risk of regulatory scrutiny and/or enforcement actions.

On July 8, 2021, reports circulated on social media that the Company's core product – the 360 IOU app, had been removed from major app stores. On this news, 360 DigiTech's stock fell $7.12 per share, or 21.48%, to close at $26.02 on July 8, 2021. Then, on July 9, Seeking Alpha reported that 360 DigiTech confirmed the removal of the 360 IOU app from the Android app store.

If you purchased shares of 360 DigiTech, Inc. (QFIN) between April 30, 2020 and July 7, 2021, you have until September 13, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against 360 DigiTech, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:QFIN

Release Versions
$Cashtags

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom